175 related articles for article (PubMed ID: 9187105)
1. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines.
Hendricks DT; Taylor R; Reed M; Birrer MJ
Cancer Res; 1997 Jun; 57(11):2112-5. PubMed ID: 9187105
[TBL] [Abstract][Full Text] [Related]
2. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
3. Fragile histidine triad transcription abnormalities and human papillomavirus E6-E7 mRNA expression in the development of cervical carcinoma.
Segawa T; Sasagawa T; Yamazaki H; Sakaike J; Ishikawa H; Inoue M
Cancer; 1999 May; 85(9):2001-10. PubMed ID: 10223242
[TBL] [Abstract][Full Text] [Related]
4. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.
Fong KM; Biesterveld EJ; Virmani A; Wistuba I; Sekido Y; Bader SA; Ahmadian M; Ong ST; Rassool FV; Zimmerman PV; Giaccone G; Gazdar AF; Minna JD
Cancer Res; 1997 Jun; 57(11):2256-67. PubMed ID: 9187130
[TBL] [Abstract][Full Text] [Related]
5. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
6. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
7. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
9. Loss of FHIT expression in gastric carcinoma.
Baffa R; Veronese ML; Santoro R; Mandes B; Palazzo JP; Rugge M; Santoro E; Croce CM; Huebner K
Cancer Res; 1998 Oct; 58(20):4708-14. PubMed ID: 9788626
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands.
Ahmadian M; Wistuba II; Fong KM; Behrens C; Kodagoda DR; Saboorian MH; Shay J; Tomlinson GE; Blum J; Minna JD; Gazdar AF
Cancer Res; 1997 Sep; 57(17):3664-8. PubMed ID: 9288768
[TBL] [Abstract][Full Text] [Related]
11. Decreased or altered expression of the FHIT gene in human leukemias.
Sugimoto K; Yamada K; Miyagawa K; Hirai H; Oshimi K
Stem Cells; 1997; 15(3):223-8. PubMed ID: 9170214
[TBL] [Abstract][Full Text] [Related]
12. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
13. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the FHIT gene and its product in squamous cell carcinomas of the head and neck.
Kisielewski AE; Xiao GH; Liu SC; Klein-Szanto AJ; Novara M; Sina J; Bleicher K; Yeung RS; Goodrow TL
Oncogene; 1998 Jul; 17(1):83-91. PubMed ID: 9671317
[TBL] [Abstract][Full Text] [Related]
15. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers.
Sorio C; Baron A; Orlandini S; Zamboni G; Pederzoli P; Huebner K; Scarpa A
Cancer Res; 1999 Mar; 59(6):1308-14. PubMed ID: 10096564
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of the human fragile histidine triad gene at 3p14.2 in monochromosomal human/mouse microcell hybrid-derived severe combined immunodeficient mouse tumors.
Kholodnyuk ID; Szeles A; Yang Y; Klein G; Imreh S
Cancer Res; 2000 Dec; 60(24):7119-25. PubMed ID: 11156420
[TBL] [Abstract][Full Text] [Related]
17. Study of FHIT transcripts in normal and malignant breast tissue.
Bièche I; Latil A; Becette V; Lidereau R
Genes Chromosomes Cancer; 1998 Dec; 23(4):292-9. PubMed ID: 9824201
[TBL] [Abstract][Full Text] [Related]
18. Expression of the fragile histidine triad gene in normal rat tissues and human kidney cancer cell lines.
Lee SH; Kim TJ; Kim HY; Kim JG; Park MK; Woo KM; Kim SH; Hwang KY; Nam HS; Min YK; Cho MH
Res Commun Mol Pathol Pharmacol; 2002; 112(1-4):145-57. PubMed ID: 15080505
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR.
Das H; Koizumi T; Sugimoto T; Chakraborty S; Ichimura T; Hasegawa K; Nishimura R
Br J Cancer; 2000 May; 82(10):1682-8. PubMed ID: 10817504
[TBL] [Abstract][Full Text] [Related]
20. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines.
Mao L; Fan YH; Lotan R; Hong WK
Cancer Res; 1996 Nov; 56(22):5128-31. PubMed ID: 8912845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
